Wire · opportunities
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
Teva received FDA approval for WELTRUZA™, the first once-monthly subcutaneous injectable olanzapine for adult schizophrenia patients, eliminating the need for loading doses, oral supplementation, or post-injection monitoring. The Phase 3 SOLARIS trial showed significant symptom improvement and illness severity reduction, supporting Teva's focus on patient-centred neuroscience innovation.
This Wire brief sits within Fusion42's coverage of Medtech, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
You can now build or sell solutions around WELTRUZA's monthly injectable format that removes patient adherence hurdles seen in daily oral schizophrenia meds. Treatment tech aimed at simplifying care routines just found a new regulatory green light in the US.
◆ Coverage
14 sources · first reported 9 Oct 2026 · latest 10 Oct 2026
◆ Topics